Latest Filings

Issuer Activity

Insider Overview :: BioSyent Inc. (V:RX) [?]
Business Focus: Pharmaceuticals
Recent Price for RX
CAD 1.19 +0.01 (+0.85%)
TSXV Delayed 15 minutes
May 23 1554 EDT
1-Day High 52-Week High P/E 1-Day Volume Mkt Cap ($Mil)
1.19 1.43 10.7 80,552 16.15
1-Day Low 52-Week Low Yield Avg. Volume  
1.17 0.54 0.0% 25,859  
Log in or sign up for a free account to add this stock to your watch list.
Holdings trends & enhanced charts available in PDF report. Click here for details »
Latest 10 SEDI filings (by transaction date) for RX within the last 6 months [?]
Amended Filing
As of 11:59pm ET May 22nd, 2013
Filing
Date 		Transaction
Date 		Insider Name Ownership
Type 		Securities Nature of transaction # or value acquired or disposed of Price
Mar 28/13 Mar 27/13 D'Souza, Alfred Indirect Ownership Common Shares 51 - Exercise of options 75,000 $0.100
Mar 28/13 Mar 27/13 D'Souza, Alfred Direct Ownership Common Shares - Options 51 - Exercise of options -75,000 $0.100
Mar 28/13 Mar 27/13 D'Souza, Alfred Indirect Ownership Common Shares 10 - Acquisition in the public market 4,700 $1.33
Mar 27/13 Mar 27/13 Larson, Douglas Robert Direct Ownership Common Shares 10 - Disposition in the public market -5,000 $1.33
Mar 28/13 Mar 25/13 D'Souza, Alfred Indirect Ownership Common Shares 10 - Acquisition in the public market 20,000 $1.30
Mar 26/13 Mar 25/13 Larson, Douglas Robert Direct Ownership Common Shares 51 - Exercise of options 170,000 $0.110
Mar 26/13 Mar 25/13 Larson, Douglas Robert Direct Ownership Common Shares - Options 51 - Exercise of options -170,000 $0.110
Mar 26/13 Mar 25/13 Larson, Douglas Robert Direct Ownership Common Shares 51 - Exercise of options 30,000 $0.100
Mar 26/13 Mar 25/13 Larson, Douglas Robert Direct Ownership Common Shares - Options 51 - Exercise of options -30,000 $0.100
Jan 3/13 Dec 21/12 Wilson, Kevin Direct Ownership Common Shares - Options 50 - Grant of options 4,100 $0.910
Sign up for an account or login above to see all SEDI filings within the past 6 months.
Latest 10 SEDI filings (by filing date) for RX within the last 6 months [?]
Amended Filing
As of 11:59pm ET May 22nd, 2013
Filing
Date 		Transaction
Date 		Insider Name Ownership
Type 		Securities Nature of transaction # or value acquired or disposed of Price
Mar 28/13 Mar 27/13 D'Souza, Alfred Indirect Ownership Common Shares 51 - Exercise of options 75,000 $0.100
Mar 28/13 Mar 27/13 D'Souza, Alfred Direct Ownership Common Shares - Options 51 - Exercise of options -75,000 $0.100
Mar 28/13 Mar 27/13 D'Souza, Alfred Indirect Ownership Common Shares 10 - Acquisition in the public market 4,700 $1.33
Mar 28/13 Mar 25/13 D'Souza, Alfred Indirect Ownership Common Shares 10 - Acquisition in the public market 20,000 $1.30
Mar 27/13 Mar 27/13 Larson, Douglas Robert Direct Ownership Common Shares 10 - Disposition in the public market -5,000 $1.33
Mar 26/13 Dec 18/12 Larson, Douglas Robert Direct Ownership Common Shares - Options 50 - Grant of options 3,900 $0.910
Mar 26/13 Feb 25/11 Larson, Douglas Robert Direct Ownership Common Shares - Options 50 - Grant of options 200,000 $0.110
Mar 26/13 Feb 12/11 Larson, Douglas Robert Direct Ownership Common Shares - Options 52 - Expiration of options -200,000 $0.100
Mar 26/13 Dec 16/10 Larson, Douglas Robert Direct Ownership Common Shares - Options 50 - Grant of options 10,000 $0.110
Mar 26/13 Mar 25/13 Larson, Douglas Robert Direct Ownership Common Shares 51 - Exercise of options 170,000 $0.110
Sign up for an account or login above to see all SEDI filings within the past 6 months.
Sign up for an account or login above to see the past 6 months of SEDI filings sorted by insider.
No Markers (TSX Insider Summaries) for RX on May 22, 2013 [?]
To view marker data for the past week, sign up for an account or log in above.
To view more history, sign up for an account at inkresearch.com
Sector:  Healthcare Industry:  Pharmaceuticals
Key People
Rene C. Goehrum
Chairman of the Board, President, Chief Executive Officer 		Alfred D'Souza
Chief Financial Officer, Vice President 		Douglas R. Larson
Secretary, Director
Company Contact
Address: Suite 520, 170 Attwell Drive
TORONTO ON M9W 5Z5
Tel: 1-905-2060013
Website: www.biosyent.com
IR: www.biosyent.com/index.php?show=page&cid=178
Business Overview
BioSyent Inc. is a life science company that acquires or licenses products and commercializes science-based technologies that advance human health and public safety. The Company's principal business activities include the marketing of pharmaceutical products in Canada and the manufacturing and marketing of non-chemical bio- and health-friendly insecticides worldwide. BioSyent's focuses on sourcing pharmaceutical products that have been developed and proven safe and effective; managing the regulatory process through to product registration (approval), and once approved, marketing these products in Canada. The Company, through its subsidiary, BioSyent Pharma Inc. launched FeraMAX, an oral hematinic, to the Canadian healthcare market. FeraMAX is indicated for the prevention and treatment of iron deficiency anaemia (IDA). The Company manufactures and markets a bio-friendly non-toxic product Protect-It. Protect-It is a non-chemical, food-safe grain insecticide.
Competitors with Recent Insider Filings
Paladin Labs (T:PLB)
Sophiris Bio (T:SHS)
Cipher Pharmaceuticals (T:DND)
 
BioSyent Inc. Insider Report Only $20.00